To investigate the adaptations of drug-resistant prostate cancer cells, we adapted the prostate tumoral cell line LNCaP, which is androgen-sensitive, to grow in the presence of the androgen receptor antagonist 2-hydroxy-flutamide (FLU) via a stepwise increase in its concentration for nine months. Here, AR is linked to prostate cancer.